Yoga for Treatment of Overactive Bladder in Pediatric Patients

Launched by DUKE UNIVERSITY · May 30, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring whether yoga can help children and teens aged 8 to 18 who have been diagnosed with an overactive bladder. An overactive bladder means that a person frequently feels the need to urinate, which can be challenging for daily life. The study will involve participants attending weekly yoga classes for six weeks to see if this practice improves their symptoms. Researchers will collect feedback through questionnaires and urine samples to measure any changes in their condition before, during, and after the yoga sessions.

To join the study, participants need to be between 8 and 18 years old and have a history of overactive bladder or urinary incontinence. They must also have consent from a parent or guardian. However, children with certain medical conditions affecting their bladder or who have untreated urinary infections will not be eligible. Throughout the study, participants will continue to receive standard medical care when they are not in the yoga sessions. This study aims to provide valuable insights into the potential benefits of yoga for managing bladder issues in young patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 8-18 years of age
• • History of non-neurogenic overactive bladder or detrusor overactivity and/or urinary incontinence (ICD 10 codes respectively - N32.81, N39.498)
• • Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPPA) authorization from the participant or the participant's parent/legal guardian
• • Minor participant is willing and able to provide assent (as applicable)
• • Vancouver Dysfunctional Elimination Syndrome\[15\] score of ≥11 and a positive modified bother score within 30 days of consent
• Exclusion Criteria:
• • Known or apparent untreated anatomical abnormality of lower urinary tract (i.e. untreated ureterocele)
• • Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)
• • Nerve damage that may impact pelvic floor function
• • History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)
• • Active, untreated UTI at the time of enrollment (UTI undergoing active treatment is allowable)
• • Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential
• • Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety